HSV innovation - BNT163

BioNTech, the German biotechnology company known for its advancements in mRNA technology, is developing an HSV vaccine candidate called BNT163. This mRNA-based vaccine aims to prevent genital herpes, specifically caused by HSV-2, by inducing a strong immune response targeting multiple viral antigens. The vaccine encodes three non-infectious HSV-2 glycoproteins, which help prevent the virus from entering cells, spreading, and countering its immunosuppressive effects.